Chongqing Precision Biotech

Chongqing Precision Biotech, based in Chongqing, China, is a cell therapy company. Precision Biotech is a Chinese biopharmaceutical company focused on cell-based drug development, specialising in CAR-T cell immunotherapies including a marketed paediatric/adolescent leukaemia CAR-T product. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in multiple myeloma. The largest, NCT04271644 (BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.